Gastroenterología y Hepatología (English Edition)最新文献

{"title":"Cricopharyngeal bar: A rare entity","authors":"Jeronimo Toro-Calle , Daniel Herrera , Maria Alejandra Mesa","doi":"10.1016/j.gastre.2025.502348","DOIUrl":"10.1016/j.gastre.2025.502348","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 6","pages":"Article 502348"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of anxiety and depression on quality of life in a cohort of inflammatory bowel disease patients from Northeastern of Brazil","authors":"Raiza Lima Silva ,&nbsp;Francisca Isabelle da Silva e Sousa ,&nbsp;Gabriel Lucas Ferreira da Silva ,&nbsp;Victória Danielly Rabelo Almeida ,&nbsp;Simão Barbosa Silva ,&nbsp;Mateus Mendes Santos Freire ,&nbsp;Marcellus Henrique Loiola Ponte de Souza ,&nbsp;Lucia Libanez Bessa Campelo Braga","doi":"10.1016/j.gastre.2025.502283","DOIUrl":"10.1016/j.gastre.2025.502283","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to assess whether the association between chronic pathologies and depressive and/or anxious disorders is high, resulting in a reduction in the patient's quality of life.</div></div><div><h3>Patients and methods</h3><div>This is a prospective cross-sectional study with a descriptive and analytical design. Sociodemographic data and lifestyle habits were collected. Subsequently, the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Hospital Anxiety and Depression Scale (HADS) were applied.</div></div><div><h3>Results</h3><div>A total of 141 patients participated in the study, with a mean age of 45.78 (SD 16.01) years, of which 60.3% were female (<em>n</em> <!-->=<!--> <!-->85) and 39.7% were male (<em>n</em> <!-->=<!--> <!-->56). 58.9% had ulcerative colitis (UC) (<em>n</em> <!-->=<!--> <!-->83), and 41.1% had Crohn's disease (CD) (<em>n</em> <!-->=<!--> <!-->58). 16.5% of patients had a previous diagnosis of generalized anxiety disorder (GAD) and/or major depression (MD) (<em>n</em> <!-->=<!--> <!-->23). Regarding IBDQ scores, participants with anxiety had significantly lower mean scores in all IBDQ items (<em>p</em> <!-->&lt;<!--> <!-->0.001), while the depression diagnosis obtained significantly lower mean values for systemic (<em>p</em> <!-->=<!--> <!-->0.015), emotional (<em>p</em> <!-->=<!--> <!-->0.001), and intestinal symptoms (<em>p</em> <!-->=<!--> <!-->0.005).</div></div><div><h3>Conclusion</h3><div>The results indicate that anxiety and depression negatively impact the quality of life of patients with IBD independently of the disease activity.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 6","pages":"Article 502283"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiphospholipid syndrome autoantibodies induction after treatment with anti-TNF alpha therapy in patients with IBD","authors":"Virginia Robles-Alonso ,&nbsp;Roser Solans ,&nbsp;Ernesto Lastiri ,&nbsp;Xavier Serra ,&nbsp;Elena Céspedes-Martínez ,&nbsp;Luís Mayorga ,&nbsp;Claudia Herrera-deGuise ,&nbsp;Francesc Casellas ,&nbsp;Natalia Borruel","doi":"10.1016/j.gastre.2025.502258","DOIUrl":"10.1016/j.gastre.2025.502258","url":null,"abstract":"<div><h3>Introduction</h3><div>Ant-iTNF treatment has been broadly linked with autoantibodies and autoimmune disorders development. After the clinical observation of aPTT (activated partial thromboplastin clotting time) prolongation in our cohort of IBD patients treated with anti-TNF, we sought to determine the presence of antiphospolipid antibodies in our population, along with antiphospholipid syndrome (APS) occurrence.</div></div><div><h3>Methods</h3><div>We included in the study 289 patients treated with anti-TNFα antibodies.</div></div><div><h3>Results</h3><div>Twenty four of 289 patients presented a prolonged aPPT (8.3%) after starting anti-TNF treatment. We found antiphospholipid antibodies in 70.8% (17/24) of patients with aPTT prolongation. No major thrombotic events were reported although one patient met criteria for APS because of persistent antiphospolipid antibodies and two miscarriages. Another patient was diagnosed with lupus-like syndrome.</div></div><div><h3>Conclusion</h3><div>Anti-TNF treatment is associated with the induction of various antibodies, among them, antiphospholipid antibodies. However, a very low number of patients develop APS. Testing for antiphospholipid antibodies patients with prolonged aPPT could identify those at risk and lead to individualized treatment. Additional prospective studies are necessary to acquire more information.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 6","pages":"Article 502258"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of relative adrenal insufficiency in patients with severe alcohol-associated hepatitis—A prospective clinical study","authors":"Raúl Alberto Jiménez-Castillo ,&nbsp;Carlos Eugenio González-Martínez ,&nbsp;Elianee María Tovar-Bojorquez ,&nbsp;Carlos Alejandro Cortez-Hernández ,&nbsp;Joel Omar Jaquez-Quintana ,&nbsp;José Alberto González-González ,&nbsp;José Gerardo González-González ,&nbsp;Héctor Jesús Maldonado-Garza","doi":"10.1016/j.gastre.2025.502322","DOIUrl":"10.1016/j.gastre.2025.502322","url":null,"abstract":"<div><h3>Background/Aims</h3><div>Relative adrenal insufficiency (RAI) is frequent in patients with liver cirrhosis and affects their prognosis. Scarce data on RAI in patients with alcohol-associated hepatitis (AAH) exists. This study aimed to document the prevalence and prognostic implication of RAI in patients with severe AAH.</div></div><div><h3>Patients and methods</h3><div>Adults with a first episode of AAH were selected. The delta cortisol level was the difference between the serum basal cortisol and 60<!--> <!-->min after ACTH stimulation. Cox proportional-hazard regression model was used for univariate analysis of prognostic factors with 95% confidence intervals. The Kaplan–Meier and log-rank tests were applied for survival analysis between patients with RAI and without RAI.</div></div><div><h3>Results</h3><div>Twenty-five subjects with a first episode of AAH were included. Eight (32.0%) deaths occurred in our cohort. Univariate analysis showed that presence of RAI (<em>p</em> <!-->=<!--> <!-->0.049) had a significant impact on 90-day Overall Survival (OS). Serum albumin (<em>p</em> <!-->=<!--> <!-->0.991), serum creatinine (<em>p</em> <!-->=<!--> <!-->0.954), sodium (<em>p</em> <!-->=<!--> <!-->0.986) and international normalized ratio (<em>p</em> <!-->=<!--> <!-->0.073) did not show a significant impact on 90-day OS. Ninety-day overall survival for patients with RAI was 50.0% vs. 90.9% in those without RAI, (<em>p</em> <!-->=<!--> <!-->0.040).</div></div><div><h3>Conclusions</h3><div>The presence of RAI seems to be a fair predictor of intermediate-term survival in AAH patients.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 6","pages":"Article 502322"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative evaluation of point of care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients","authors":"Carles Iniesta-Navalón ,&nbsp;Manuel Ríos-Saorín ,&nbsp;Lorena Rentero-Redondo ,&nbsp;Rebeca Añez-Castaño ,&nbsp;Elena Urbieta-Sanz","doi":"10.1016/j.gastre.2025.502277","DOIUrl":"10.1016/j.gastre.2025.502277","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the analytical performance and clinical utility of the POC-AFIAS assay in comparison with two ELISA established assays for quantifying serum concentrations of ustekinumab.</div></div><div><h3>Methods</h3><div>A prospective study was conducted. Consecutive serum samples from adult patients undergoing treatment with ustekinumab were collected. Three analytical techniques were compared for the quantification of ustekinumab serum concentrations: the AFIAS-10® POC assay (POC-AFIAS), the Promonitor® ELISA assay (ELISA-PRO), and the ELISA Ridascreen® assay (ELISA-RDSC). Ustekinumab concentrations were evaluated within three therapeutic ranges: &lt;1<!--> <!-->μg/mL, 1–4.5<!--> <!-->μg/mL, and &gt;4.5<!--> <!-->μg/mL. Statistical analysis included Pearson correlation, intra-class correlation coefficient, and Bland–Altman analysis.</div></div><div><h3>Results</h3><div>A total of 104 patients were included in the study. The median ustekinumab concentrations measured were 5.22<!--> <!-->μg/mL (POC-AFIAS), 3.99<!--> <!-->μg/mL (ELISA-PRO), and 4.50<!--> <!-->μg/mL (ELISA-RDSC). Strong correlations were observed between techniques (POC-AFIAS and ELISA-PRO: <em>r</em> <!-->=<!--> <!-->0.921, POC-AFIAS and ELISA-RDSC: <em>r</em> <!-->=<!--> <!-->0.940, ELISA-PRO and ELISA-RDSC: <em>r</em> <!-->=<!--> <!-->0.976). The Bland–Altman analysis revealed a bias difference of 1.81<!--> <!-->μg/mL between POC-AFIAS and ELISA-PRO, and 1.27<!--> <!-->μg/mL between POC-AFIAS and ELISA-RDSC. Agreement rates varied by therapeutic range, with the highest agreement observed within the therapeutic range (97.3%) and lower agreement for supra-therapeutic concentrations (74.6%).</div></div><div><h3>Conclusion</h3><div>This study demonstrated that the POC-AFIAS assay provides comparable results to established ELISA techniques for quantifying serum concentrations of ustekinumab, particularly within the therapeutic range. The findings suggest that the POC-AFIAS assay offers a rapid and effective tool for managing ustekinumab therapy in clinical practice.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 6","pages":"Article 502277"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficiency of artificial intelligence for management and clinical decision-making in the identification of patients with hidden HCV infection (Intelligen-C strategy)","authors":"José Luis Castro Urda ,&nbsp;Marta Álvarez ,&nbsp;Helena Cantero ,&nbsp;Victoria Ayala ,&nbsp;Marta Vázquez ,&nbsp;Javier Castro ,&nbsp;Laura Salinas-Ortega ,&nbsp;Raquel Domínguez-Hernández","doi":"10.1016/j.gastre.2025.502362","DOIUrl":"10.1016/j.gastre.2025.502362","url":null,"abstract":"<div><h3>Introduction</h3><div>Artificial intelligence (AI) allows the optimization of diagnostic processes for hepatitis C virus (HCV) patients. Our objective was to evaluate the clinical, economic, and management benefits of an AI-based clinical decision support system (Intelligen-C strategy).</div></div><div><h3>Methods</h3><div>The Intelligen-C strategy consisted of (1) a retrospective phase (Dec 2013–Sep 2021), in which medical records were reviewed to search for anti-HCV-positive and/or HCV-RNA+ patients lost in the system, and (2) a prospective phase (Feb 2022–Jan 2023), in which automated screening (40–70 years) and routine testing for risk factors were performed in patients who were admitted to the emergency department or were hospitalized. With the use of automated screening, the system identified patients without an HCV diagnosis among those requiring blood tests and requested HCV serology; if the results were positive, reflex testing for HCV-RNA was performed. If a patient was HCV-RNA+, an alert was generated and sent to the hepatology department. In addition, the prospective phase was compared with the previous period to evaluate its effectiveness and efficiency.</div></div><div><h3>Results</h3><div>In the retrospective phase, the Intelligen-C strategy allowed the identification of 272 anti-HCV- or HCV-RNA+ patients who were lost to follow-up, of whom 11 were treated; in the prospective phase, after 7312 serologies were performed, 28 HCV-RNA+ patients were identified, 14 attended the appointment, and 9 were treated. In the prospective phase vs. the previous period, increased serology (7312 vs. 909), HCV-RNA+ detection (28 vs. 3), and treated patients (9 vs. 1) generated savings to the health system related to medical visits. In addition, Intelligen-C was cost-effective.</div></div><div><h3>Conclusions</h3><div>The implementation of the Intelligen-C strategy allowed the identification of patients with undiagnosed infection, facilitated their diagnosis, reduced healthcare processes and associated hospital costs, and proved to be efficient.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 6","pages":"Article 502362"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic ultrasound-directed transgastric ERCP (EDGE) – An effective approach for bile duct stone treatment after gastric bypass","authors":"Ivo Mendes ,&nbsp;Francisco Vara-Luiz ,&nbsp;Gonçalo Nunes ,&nbsp;Júlio Veloso ,&nbsp;Jorge Fonseca ,&nbsp;Pedro Pinto-Marques","doi":"10.1016/j.gastre.2025.502293","DOIUrl":"10.1016/j.gastre.2025.502293","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 6","pages":"Article 502293"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel Disease","authors":"Mariam Aguas Peris ,&nbsp;Javier del Hoyo Francisco ,&nbsp;Pilar Nos Mateu ,&nbsp;Ana Echarri Piudo ,&nbsp;Marta Calvo Moya ,&nbsp;Beatriz Gros ,&nbsp;María Dolores Martín-Arranz ,&nbsp;Emilio Monte Boquet ,&nbsp;Sergio Inglán Agustín ,&nbsp;Antonio Valdivia Martínez ,&nbsp;Marisa Correcher ,&nbsp;Manuel Barreiro-de Acosta ,&nbsp;Miriam Mañosa Ciria ,&nbsp;Francisco Rodriguez-Moranta ,&nbsp;Yamile Zabana ,&nbsp;Ana Gutiérrez Casbas","doi":"10.1016/j.gastre.2025.502320","DOIUrl":"10.1016/j.gastre.2025.502320","url":null,"abstract":"<div><div>Inflammatory Bowel Disease (IBD) is a chronic digestive condition that requires continuous monitoring by healthcare professionals to determine appropriate therapy and manage short- and long-term complications. Telemedicine has become an essential approach for managing chronic conditions such as IBD, improving care accessibility and continuity, decreasing hospitalization rates, and optimizing patient follow-up. It enables rapid treatment adjustments and encourages patient self-management. Additionally, it reduces the burden on the healthcare system by decreasing unnecessary in-person visits and provides real-time support, thereby improving quality of life and clinical outcomes.</div><div>The objective of this position statement by the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) is to establish recommendations for the use of telemedicine in its different modalities (teleconsulting, telemonitoring, mobile applications and telepharmacy) for patients with IBD and address the legal, ethical, and technical aspects necessary for its proper implementation.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 6","pages":"Article 502320"},"PeriodicalIF":0.0,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of esophageal squamous cell carcinoma with head and neck cancer","authors":"Cautar El Maimouni,&nbsp;Henry Córdova,&nbsp;Sterling Feliz-Ruiz,&nbsp;Irina Luzko Scheid,&nbsp;Leticia Moreira,&nbsp;Joan Llach,&nbsp;Isis K. Araujo,&nbsp;Begoña González-Suárez,&nbsp;Àngels Ginés,&nbsp;Gloria Fernández-Esparrach","doi":"10.1016/j.gastre.2025.502318","DOIUrl":"10.1016/j.gastre.2025.502318","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Esophageal squamous cell carcinomas (ESCC) are often accompanied by head and neck squamous cell carcinoma (HNSCC) and vice versa. Our study aimed to describe the prevalence of HNSCC in patients with ESCC, the chronology of appearance and the impact on survival.</div></div><div><h3>Methods</h3><div>A retrospective review was carried out through a computerized database of patients diagnosed with ESCC at Hospital Clinic of Barcelona between January 1999 and June 2019. Demographic data, date of ESCC diagnosis, survival time, primary tumor location, diagnosis of HNSCC and chronological relationship were recorded.</div></div><div><h3>Results</h3><div>A total of 231 patients with ESCC confirmed histologically were included in the study with a median age of 64 years (IQR, 56.0–72.0), and 178 (77%) were male. The majority of the patients had a history of smoking and alcohol consumption (69.7% and 60.6%, respectively). The predominant location of ESCC was the middle esophagus (<em>n</em> <!-->=<!--> <!-->124, 53.7%).</div><div>Forty-one patients (17.7%) had HNSCC: 21 (51.2%) were previous, 14 (34.1%) synchronous and 6 (14.6%) metachronous.</div><div>All the patients were followed and 196 (84.8%) died with a median survival time of 19 months (IQR, 7–66). There were not statistically significant differences among the living patients and the deceased.</div></div><div><h3>Conclusions</h3><div>In our setting, a 17.7% of patients with ESCC have an associated HNSCC with no significant differences in survival between patients with both ESCC and HNSCC compared to those with only ESCC. However, the implementation of a screening program could allow the detection of a second primary tumor at early stages.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 5","pages":"Article 502318"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Externalized nurse-led model for hepatitis C virus microelimination and impact of drug use profile","authors":"Anna Miralpeix ,&nbsp;Paula Ibáñez ,&nbsp;Víctor Navarro ,&nbsp;Patricia Colomera ,&nbsp;Montserrat Gálvez ,&nbsp;Zoe Mariño ,&nbsp;Xavier Major ,&nbsp;Joan Colom ,&nbsp;Xavier Forns ,&nbsp;Sabela Lens","doi":"10.1016/j.gastre.2025.502288","DOIUrl":"10.1016/j.gastre.2025.502288","url":null,"abstract":"<div><h3>Background and objective</h3><div>Direct-acting antivirals have greatly simplified the treatment of hepatitis C virus (HCV), yet circuits that bring diagnosis and treatment closer to people who inject drugs (PWID) are needed to achieve the elimination targets of the WHO. With this purpose we have established an externalized nurse-driven circuit among former and active PWID in an addiction centre (AC) and a harm reduction centre (HRC).</div></div><div><h3>Methods and settings</h3><div>The nursing staff offered HCV screening, diagnosis and treatment to the AC and HRC users, administered medication after the hepatologist's remote prescription to those with an active infection who accepted being treated, and implemented educational and harm reduction interventions.</div></div><div><h3>Participants and results</h3><div>Between October 2018 and March 2021, 566 users accepted screening. 134 (24%) had an active infection, with a higher prevalence among HRC users (42% vs 17%; <em>p</em> <!-->&lt;<!--> <!-->0.001), who were more frequently foreigners, homeless and reported active drug use and syringe sharing. Treatment initiation was similar between groups. Overall sustained viral response (SVR) for intention-to-treat (ITT) and per protocol (PP) was 70% and 88% respectively. Overall adherence was good in both groups; however, SVR was higher in AC users compared to HRC users (ITT-SVR 81% vs 55%). All reinfections (6% by ITT) occurred in the HRC group. Overall loss to follow-up rate was 21%.</div></div><div><h3>Conclusions</h3><div>This patient-centred nurse-driven circuit demonstrates that HCV treatment can be successfully delivered to PWID even with active drug use and socio-economic complexity. User-specific characteristics need to be considered when setting up these interventions to maximize success.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 5","pages":"Article 502288"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}